AstraZeneca Pharma India Limited
Quality (59/100) does the heavy lifting; valuation (1/100) is the drag.
ExpensiveOvervaluedStocksWizard rates AstraZeneca Pharma India Limited a Sell, scoring 30/100 on our blended model. On 107.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 17% below its 52-week high of ₹9,783.79 and 5% above the low of ₹7,730.96. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 0/9. It clears 5 of 13 investability checks, with durability 59, valuation 2 and momentum 29 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹3,240.
1-year price
EOD · 2026-07-3152-week range
-17.21% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell30Piotroski F-score 0/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 22.8%
- Pass: Low debt (D/E < 0.5): 0.13x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 20%
- Fail: Earnings growing: -23%
- Fail: Net margin ≥ 10%: 8.2%
- Pass: Current ratio > 1.5: 1.77
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 12.15
- Fail: Piotroski ≥ 7: 0/9
Quarterly results
Annual financials
Shareholding
- Promoter81.6%
- Institutions7.8%
- Public & other10.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (22.8%).
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 12.15.
Opportunities
- Revenue growing (20% YoY).
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (0/9).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited manufactures, markets, and trades pharmaceutical products in India and internationally. Its portfolio includes medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology drugs such as TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex; the rare disease medicine Koselugo; and respiratory treatments including Symbicort and Fasenra.
AstraZeneca Pharma India Limited — frequently asked questions
Is AstraZeneca Pharma India Limited a buy, hold or sell?
StocksWizard currently rates AstraZeneca Pharma India Limited (ASTRAZEN) a Sell, based on a blended score of 30/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is AstraZeneca Pharma India Limited's fair value?
Our blended DCF and relative-valuation model estimates AstraZeneca Pharma India Limited's fair value at about ₹4,050, versus a current price of ₹8,100 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is AstraZeneca Pharma India Limited financially healthy?
AstraZeneca Pharma India Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 0/9.
How has AstraZeneca Pharma India Limited's share price performed?
AstraZeneca Pharma India Limited is down 1% over three months, and last traded at ₹8,100. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.